PRoFESS(R) Results Announced at XVII European Stroke ...(yer Schering Pharma and GlaxoSmithKline....),Health

About Stroke

Stroke is the third-leading cause of death and a leading cause of chronic adult disability in the United States.(3) There are approximately 5.8 million stroke survivors in the United States,(4) and 21.5 percent of people who survive a first stroke or transient ischemic attack (TIA or "mini stroke"), will experience another episode within five years.(3)

About Aggrenox(R)

Aggrenox(R) (aspirin / extended-release dipyridamole) 25mg / 200mg capsules combine a low dose of aspirin and extended-release dipyridamole to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. AGGRENOX is the only combination drug that has shown superiority to low-dose aspirin in a head-to-head trial for the prevention of recurrent stroke with a comparable safety profile.

The most common adverse event with AGGRENOX was headache (38.2% vs 32.4% with placebo), which was more frequent at the onset of therapy but diminished over time. In ESPS 2, GI bleeding with AGGRENOX was comparable to aspirin (4.1% vs 3.2%) and the incidence of intracranial hemorrhage was nine (9) patients (0.6%) in the AGGRENOX group, six (6) patients (0.5%) in the extended-release dipyridamole group, six (6) patients (0.4%) in the aspirin group and seven (7) patients (0.4%) in the placebo group.

AGGRENOX contains aspirin. Patients who consume three or more alcoholic drinks every day should be counseled about the bleeding risks involved with chronic, heavy alcohol use while taking aspirin. Even low doses of aspirin can increase bleeding time, which can adversely affect patients with bleeding disorders. Patients with a history of active peptic ulcer disease should avoid using aspirin, which can cause gastric mucosal irritation and bleeding. AGGRENOX should be avoided in the third trimester of pregnancy.

For more information including complete Prescribin
'/>"/>